

A recently published meta-analysis suggests 3M™ Veraflo™ Therapy could become your new standard of care.

A meta-analysis of 13 studies with 720 patients reported Veraflo Therapy had a significant effect on clinical outcomes when compared to standard of care including 3M™ V.A.C.® Therapy.



Length of therapy reduced by more than half
(9.88 days vs 21.8 days, $p=0.02$)^{1,2}



Wounds were **2.39 times more likely to close**
($p=0.01$)¹

You know the science behind V.A.C.® Therapy.

Now, know the data behind Veraflo Therapy.



To learn more about why you should **Start Smart** with Veraflo Therapy, please contact your local Sales Executive or visit 3M.ca/connect

References:

1. Gabriel A, Camardo M, O'Rourke E, Gold R, Kim PJ. Effects of Negative-Pressure Wound Therapy With Instillation versus Standard of Care in Multiple Wound Types: Systematic Literature Review and Meta-Analysis. *Plast Reconstr Surg*. 2021 Jan 1;147(1S-1):68S-76S. doi: 10.1097/PRS.00000000000007614. PMID: 33347065.
2. Camardo, Mark. "Veraflo Meta-Analysis Standardized and Non-Standardized Means.", 3M Internal Report, San Antonio, Texas, 2020.

Available in Canada from your authorized 3M-KCI distributors.
KCI USA, Inc., a 3M Company
KCI owned and operated by 3M Company

KCI Medical Canada Inc.
75 Courtneypark Dr W, Unit 4
Mississauga, ON
L5W 0E3

KCI USA, INC.
12930 IH 10 West
San Antonio, TX
78249

NOTE: Specific indications, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. This material is intended for healthcare professionals.

© 2022 3M. All rights reserved. 3M and the other marks shown are marks and/or registered marks. Unauthorized use prohibited. Used under license in Canada. PRA-PM-CA-00192 (03/21) 2201-2290-E